Ninety-minute Daratumumab infusions for relapsed and refractory multiple myeloma: two years of Italian single-centre observational study

Daratumumab was the first fully human anti-CD38 monoclonal antibody (mAb) to be tested in clinical trials1, demonstrating efficacy as a single agent in patients with relapsed/refractory multiple myeloma (RRMM). Daratumumab exerts direct anti-tumor and indirect immunomodulatory effects by targeting CD38, a cell surface receptor highly expressed on neoplastic plasma cells2,3. Daratumumab was first approved in patients with RRMM as monotherapy4 and subsequently in combination with proteasome inhibitors (PIs, Dara-VD)5,6 or immunomodulatory drugs (IMiDs, Dara-RD)7; currently, it is employed also for the treatment of newly diagnosed patients with MM who are not candidate for autologous stem cell transplantation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the editor Source Type: research